Our group is strongly committed to translating bench discoveries into clinical applications. For over 20 years, we have been developing innovative oncolytic adenoviruses (oAdVs) designed to selectively replicate within tumor tissue. Following the initial tumor attack, these oAdVs induce a secondary antitumor immune response and an abscopal effect, enhanced by the incorporation of immunomodulators into the viral genome.
More recently, we have further “armed” our oAdVs with BiTEs and checkpoint inhibitors derived from our proprietary nanobody libraries. In addition, ongoing studies are exploring the combination of our oAdVs with mesenchymal stem cells and, through an international collaboration, with CAR-T cells. Additionally, we have integrated CRISPR technology to target mechanisms of cancer resistance to treatment.
Beyond our immunotherapeutic strategies, our group actively participates in national and multinational applied genomics programs in cancer research. These initiatives aim to elucidate potential mechanisms that dictate and predict patient responses to specific treatment including the use of molecular signature.